Holen Sie sich die Stockscreener-App
1.47
0.68%
0.01
Vorhandelsmarkt:
1.46
-0.01
-0.68%
Schlusskurs vom Vortag:
$1.46
Offen:
$1.53
24-Stunden-Volumen:
1.02M
Relative Volume:
1.20
Marktkapitalisierung:
$109.12M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-11.45%
1M Leistung:
-58.71%
6M Leistung:
-96.36%
1J Leistung:
+0.00%
1-Tages-Spanne:
$1.46
$1.8443
1-Wochen-Bereich:
$1.43
$2.094
52-Wochen-Spanne:
$1.43
$67.00
Jyong Biotech Ltd Stock (MENS) Company Profile
Firmenname
Jyong Biotech Ltd
Sektor
Branche
Telefon
-
Adresse
-
Compare MENS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
1.47 | 108.38M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Jyong Biotech Ltd Aktie (MENS) Neueste Nachrichten
Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia - The Manila Times
Prostate cancer therapy also lowers cholesterol in 2-year trial - Stock Titan
CEO Fu-Feng Kuo, Jyong Biotech Ltd.'s (NASDAQ:MENS) largest shareholder sees value of holdings go down 23% after recent drop - Yahoo Finance
Jyong Biotech appoints Wei (Vivi) Zhang as chief financial officer By Investing.com - Investing.com South Africa
Jyong Biotech appoints Wei (Vivi) Zhang as chief financial officer - Investing.com
Jyong Biotech Appoints Veteran Capital Markets Executive Wei Zhang as Chief Financial Officer - TipRanks
Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Update - MarketBeat
Jyong Biotech subsidiary announces phase II data for MCS-8 - TipRanks
Jyong Biotech reports positive results from MCS-8 phase II trial - Investing.com
Prostate cancer trial drug also improves cholesterol in 2-year study - stocktitan.net
Jyong Biotech Reports Higher Assets but Deeper Shareholders’ Deficit in June 2025 Unaudited Results - TipRanks
Jyong Biotech Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025 - MarketScreener
Jyong Biotech 'not aware' of any material information amid share price movement - MSN
After the recent decline, Jyong Biotech Ltd. (NASDAQ:MENS) CEO Fu-Feng Kuo's holdings have lost 33% of their value - simplywall.st
Sidus Space, Starfighters Space And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Jyong Biotech (NASDAQ:MENS) Shares Gap UpStill a Buy? - MarketBeat
Jyong Biotech Ltd.(NasdaqGM: MENS) added to NASDAQ Biotechnology Index - marketscreener.com
Jyong Biotech addresses share price fluctuations amid lock-up expiry By Investing.com - Investing.com Nigeria
Jyong Biotech in Talks With Funds Interested in Buying Shares - marketscreener.com
Jyong Biotech addresses share price fluctuations amid lock-up expiry - Investing.com
Jyong Biotech in talks with investment funds for purchasing co's ordinary shares - marketscreener.com
Jyong Biotech ‘not aware’ of any material information amid share price movement - TipRanks
Jyong Biotech Responds to Share Price and Volume Movement - The Manila Times
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Jyong Biotech (NASDAQ:MENS) Reaches New 52-Week LowHere's Why - MarketBeat
Small U.S. Stocks Decrease; Jyong Biotech Falls Furthest - 富途牛牛
Small U.S. Stocks Close Lower; Jyong Biotech Falls Furthest - 富途牛牛
Jyong Biotech (NASDAQ:MENS) Stock Price Down 19.3%Here's What Happened - MarketBeat
Jyong Biotech (NASDAQ:MENS) Shares Gap DownWhat's Next? - MarketBeat
Certain Ordinary Shares of Jyong Biotech Ltd. are subject to a Lock-Up Agreement Ending on 15-DEC-2025. - marketscreener.com
Jyong Biotech Shares Becomes Oversold (MENS) - Nasdaq
Jyong Biotech (NASDAQ:MENS) Trading Down 5.9%Here's Why - MarketBeat
Jyong Biotech Ltd.'s (NASDAQ:MENS) Lock-Up Period Will End on December 15th - MarketBeat
Jyong Biotech Ltd.’s (NASDAQ:MENS) Lock-Up Period Will End on December 15th - Defense World
Jyong Biotech (NASDAQ:MENS) Shares Gap Down – Here’s Why - Defense World
Taiwan's Jyong Biotech expands regional partnership with MoU signing in Vietnam - BioSpectrum Asia
Jyong Biotech (NASDAQ:MENS) Stock Price Down 4.3%Time to Sell? - MarketBeat
Jyong Biotech expands regional partnerships, signs MoU with a Vietnam pharmaceutical distributor - marketscreener.com
Jyong Biotech Expands Regional Partnerships, Signs MoU With A Vietnam Pharmaceutical Distributor - TradingView — Track All Markets
Jyong Biotech Expands Regional Partnerships, Signs MOU with - GlobeNewswire
Jyong Biotech (MENS) Stock Analysis Report | Financials & Insights - Benzinga
Jyong Biotech (NASDAQ:MENS) Trading Up 15.1%Here's What Happened - MarketBeat
Jyong Biotech: Speculative BPH And Prostate Cancer Prevention Story (NASDAQ:MENS) - Seeking Alpha
Jyong Biotech (NASDAQ:MENS) Stock Price Down 9.6%What's Next? - MarketBeat
Finanzdaten der Jyong Biotech Ltd-Aktie (MENS)
Es liegen keine Finanzdaten für Jyong Biotech Ltd (MENS) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.24%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):